Skip to main content

Volume 16 Supplement 1

Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Meeting abstracts

Edited by Johannes-Peter Stasch, John Burnett, Harald Schmidt, Michaela Kuhn and Franz Hofmann

Publication of this supplement has been fully funded by FEBGLA e.V. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.

7th International Conference on cGMP Generators, Effectors and Therapeutic Implications. Go to conference site.

Trier, Germany19-21 June 2015

Concatenated PDF V16 S1

Page 3 of 3

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.8
    5-year Journal Impact Factor: 2.8
    Source Normalized Impact per Paper (SNIP): 0.774
    SCImago Journal Rank (SJR): 0.710

    Speed 2023
    Submission to first editorial decision (median days): 25
    Submission to acceptance (median days): 178

    Usage 2023
    Downloads: 790,731
    Altmetric mentions: 400

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Sign up for article alerts and news from this journal